

Research Article

Molecular Network of NLRP3 Inflammasome Activation-Responsive Genes in a Human Monocyte Cell Line

Natsuki Kawana, Yoji Yamamoto, Yoshihiro Kino and Jun-ichi Satoh*

Department of Bioinformatics and Molecular Neuropathology, Meiji Pharmaceutical University, Japan

*Corresponding author: Jun-ichi Satoh, Department of Bioinformatics and Molecular Neuropathology, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan, Tel and Fax: +81-42-495-8678; Email: satoj@my-pharm.ac.jp

Received: May 05 2014; Accepted: June 11 2014;

Published: June 13 2014

Abstract

Background: Inflammasome, activated by pathogen-derived and host-derived danger signals, constitutes a multimolecular signaling complex that serves as a platform for caspase-1 (CASP1) activation and interleukin-1 β (IL-1 β) maturation. The activation of NLRP3 inflammasome requires two-step signals. The first “priming” signal enhances gene expression of inflammasome components. The second “activation” signal promotes the assembly of inflammasome components. Deregulated activation of NLRP3 inflammasome contributes to the pathological processes of Alzheimer’s disease (AD) and multiple sclerosis (MS). However, at present, the precise mechanism regulating NLRP3 inflammasome activation and deactivation remains largely unknown.

Methods: By genome-wide gene expression profiling, we studied the molecular network of NLRP3 inflammasome activation-responsive genes in a human monocyte cell line THP-1 sequentially given two-step signals.

Results: We identified the set of 83 NLRP3 inflammasome activation-responsive genes. Among them, we found the NR4A nuclear receptor family NR4A1, NR4A2, and NR4A3, the EGR family EGR1, EGR2, and EGR3, the κ B family NFKBIZ, NFKBID, and NFKBIA as a key group of the genes that possibly constitute a negative feedback loop for shutting down inflammation following NLRP3 inflammasome activation. By molecular network analysis, we identified a complex network of NLRP3 inflammasome activation-responsive genes involved in cellular development and death, and immune and inflammatory responses, where transcription factors AP-1, NR4A, and EGR serve as a hub.

Conclusion: NLRP3 inflammasome activation-responsive genes constitute the molecular network composed of a set of negative feedback regulators for prompt resolution of inflammation.

Keywords: Inflammasome; NLRP3; NR4A1; NR4A2; NR4A3


Introduction

Inflammasome serves as a multi molecular signaling complex involved in activation of caspase-1 (CASP1) and maturation of interleukin-1 β (IL-1 β) and IL-18 [1,2]. A wide variety of exogenous and endogenous stimuli, characterized by microbe-derived pathogen-associated molecular patterns (PAMPs) and host- or environment-derived danger-associated molecular patterns (DAMPs), are recognized by an intracellular sensor called the NOD-like receptors (NLRs), resulting in rapid induction of inflammasome formation by ordered assembly of self-oligomerizing components.

Among various classes of inflammasome, the nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing 3 (NLRP3) inflammasome has been most intensively studied. It is composed of NLRP3, the adaptor molecule named apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), and the precursor form of the cysteine protease pro-CASP1 [1,2]. NLRP3 contains a central nucleotide-binding and oligomerization (NACHT) domain essential for activation of the signaling complex via ATP-dependent oligomerization, flanked by a C-terminal leucine-rich repeat (LRR) pivotal for ligand sensing and autoregulation and a N-terminal pyrin (PYD) domain involved

in a homotypic protein-protein interaction between NLRP3 and ASC. The molecular interaction of NLRP3 with ASC recruits pro-CASP1 by a homotypic interaction of caspase activation and recruitment (CARD) domains between ASC and pro-CASP1. Subsequently, the proximity-induced pro-CASP1 oligomerization causes autocatalytic activation of CASP1, resulting in processing of pro-IL-1 β or pro-IL-18 into biologically active IL-1 β and IL-18. Both of them act as a central regulator for induction of cytokines and chemokines that amplify inflammation by recruiting immune effector cells.

The activation of NLRP3 inflammasome requires two-step signals (Figure 1) [3,4]. The first “priming” signal termed Signal 1, such as microbe-derived lipopolysaccharide (LPS), enhances gene expression of inflammasome components and target proteins via activation of transcription factor nuclear factor-kappa B (NF- κ B). The second “activation” signal termed Signal 2 promotes the organized assembly of inflammasome components. The second signal involves three major mechanisms, such as generation of reactive oxygen species (ROS), lysosomal protease leakage, and the potassium efflux [1,2]. Mitochondria often serve as the principal source of ROS. Blockade of mitophagy induces accumulation of ROS-generating mitochondria that activates NLRP3 inflammasome [5]. Furthermore, oxidized



mitochondrial DNA directly activates NLRP3 inflammasome following induction of apoptosis [6]. By serving as an inducer of two-step signals, a diverse range of danger signals armed with PAMPs, such as *Listeria monocytogenes*, *Candida albicans*, and influenza A virus and those with DAMPs, such as amyloid-β (Aβ), uric acid and cholesterol crystals, asbestos, silica, alum, hyaluronan, and adenosine 5'-triphosphate (ATP), promptly activate the NLRP3 inflammasome [7,8].

Deregulated activation of NLRP3 inflammasome contributes to the pathological processes of various diseases, such as type 2 diabetes, Alzheimer’s disease (AD), and multiple sclerosis (MS) [9-11]. Lack of NLRP3 inflammasome components skews microglial cells to an anti-inflammatory M2 phenotype with an enhanced capacity of amyloid-β (Aβ) clearance in a mouse model of AD [10]. *Nlrp3*-knockout mice showed reduced severity of experimental autoimmune encephalomyelitis (EAE), a mouse model of MS, characterized by substantial attenuation of inflammation, demyelination and astrogliosis [12]. In active inflammatory demyelinating lesions of MS, reactive astrocytes and perivascular macrophages expressed all three components of NLRP3 inflammasome, such as NLRP3, ASC, and CASP1, along with IL-1β, suggesting that biochemical agents and monoclonal antibodies designed to block specifically NLRP3 inflammasome activation might be highly effective in treatment of active MS [11]. However, at present, the precise mechanism regulating NLRP3 inflammasome activation and deactivation remains largely unknown. In the present study, by genome-wide gene expression profiling, we attempt to clarify the comprehensive molecular network of NLRP3 inflammasome activation-responsive genes in a human monocyte cell line given consecutively two-step signals.


Materials and Methods

NLRP3 inflammasome activation

A human monocyte cell line THP-1 was obtained from RIKEN Cell Bank (Saitama, Japan). The cells were maintained in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS), 55 μM 2-mercaptoethanol, 2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin (feeding medium). To load the Signal 1, the cells were incubated for 3 hours with or without 0.2 μg/ml lipopolysaccharide (LPS; Sigma, St. Louis, MO, USA). To load the Signal 2, they were washed twice by Phosphate-Buffered Saline (PBS) and incubated further for 0.5 or 2 hours with 10 μM nigericin sodium salt (Wako Pure Chemical, Osaka, Japan) dissolved in ethanol or the equal v/v% concentration of ethanol (vehicle). Then, protein extract of the cells was processed for western blot analysis with a rabbit antibody against the C-terminal peptide of the human CASP1 p10 protein (sc-515, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and a rabbit antibody against the peptide mapping at amino acid residues of 117-269 of the human IL-1β protein (sc-7884, Santa Cruz Biotechnology).

Microarray analysis

Total cellular RNA was isolated by using the TRIZOL plus RNA Purification kit (Invitrogen). The quality of total RNA was evaluated on Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). Three hundred ng of total RNA was processed for cDNA synthesis, fragmentation, and terminal labeling with the GeneChip Whole Transcript Sense Target Labeling and Control Reagents (Affymetrix, Santa Clara, CA, USA). Then, the labeled cRNA was processed for hybridization at 45°C for 17 hours with Human Gene 1.0 ST Array (28,869 genes; Affymetrix). The arrays were washed in the



Gene Chip Fluidic Station 450 (Affymetrix), and scanned by the Gene Chip Scanner 3000 7G (Affymetrix). The raw data were expressed as CEL files and normalized by the Robust Multi Array average (RMA) method with the Expression Console software (Affymetrix).

Quantitative reverse transcription (RT)-polymerase chain reaction (qPCR) analysis

DNase-treated total RNA isolated from THP-1 cells was processed for cDNA synthesis using oligo(dT)₁₂₋₁₈ primers and Super Script II reverse transcriptase (Invitrogen). Then, cDNA was amplified by PCR in Light Cycler ST300 (Roche Diagnostics, Tokyo, Japan) using SYBR Green I and a panel of sense and antisense primer sets following: 5'ccagcactgccaactggactact3' and 5' acagctcagcaagccaggatct3' for an 162 bp product of nuclear receptor subfamily 4, group A, member 1 (NR4A1); 5'ccaagccgaccaagacgtctt3' and 5'ctgtgcaagaccacccttgc3' for an 124 bp product of nuclear receptor subfamily 4, group A, member 2 (NR4A2); 5'gaggctgcaagggcttttcaag3' and 5' gaggctgagaaggttctgtgt3' for a 242 bp product of nuclear receptor subfamily 4, group A, member 3 (NR4A3); and 5'ccatgttcgcatgggtgtgaacca3' and 5'gccagtagaggcaggatgatgttc3' for a 251 bp product of the glyceraldehyde-3-phosphate dehydrogenase (G3PDH) gene that serves as an endogenous control. The expression levels of target genes were standardized against the levels of G3PDH detected in the corresponding cDNA samples. All the assays were performed in triplicate.

Molecular network analysis

To identify biologically relevant molecular networks, we imported corresponding Entrez Gene IDs into Ingenuity Pathways Analysis (IPA) (Ingenuity Systems, Redwood City, CA, USA), KeyMolnet (Institute of Medicinal Molecular Design, Tokyo, Japan), or Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) 9.1. STRING is an open-access database, while IPA and KeyMolnet are

commercial resources.

STRING is a database that contains known and predicted, physiological and functional protein-protein interactions composed of 5,214,234 proteins from 1133 organisms [13]. STRING integrates the information from numerous resources, including experimental repositories, computational prediction methods, and public text collections. By uploading the list of UniProt IDs or Gene Symbols, STRING illustrates the union of all possible association networks.

IPA is a knowledgebase that contains approximately 3,000,000 biological and chemical interactions and functional annotations with definite scientific evidence. By uploading the list of Gene IDs and expression values, the network-generation algorithm identifies focused genes integrated in a global molecular network. IPA calculates the score p-value that reflects the statistical significance of association between the genes and the networks by the Fisher's exact test.

KeyMolnet contains knowledge-based contents on 164,000 relationships among human genes and proteins, small molecules, diseases, pathways and drugs [14]. They include the core contents collected from selected review articles with the highest reliability. By importing the list of Gene ID and expression values, KeyMolnet automatically provides corresponding molecules as nodes on the network. The neighboring network-search algorithm selected one or more molecules as starting points to generate the network of all kinds of molecular interactions around starting molecules, including direct activation/inactivation, transcriptional activation/repression, and the complex formation within one path from starting points. The generated network was compared side by side with 501 human canonical pathways of the KeyMolnet library. The algorithm counting the number of overlapping molecular relations between the extracted network and the canonical pathway makes it possible to identify the canonical pathway showing the most significant contribution to the




Figure 3: Upregulated expression of NR4A family members in THP-1 cells during NLRP3 inflammasome activation. The levels of expression of NR4A1, NR4A2, and NR4A3 transcripts in THP-1 cells following exposure to 0.2 $\mu\text{g/ml}$ LPS for 3 hours (Signal 1; S1), followed by exposure to 10 μM nigericin for 2 hours (Signal 2; S2) were determined by qPCR. They were standardized against the levels of G3PDH detected in the corresponding cDNA samples. The panels (a-c) indicate qPCR of (a) NR4A1, (b) NR4A2, and (c) NR4A3. The bars represent CNT (LPS -, nigericin -), S1 (LPS +, nigericin -), and S1+S2 (LPS+, nigericin +).

extracted network.

Results

NLRP3 inflammasome activation in THP-1 cells following introduction of two-step signals

First, by western blot analysis, we studied NLRP3 inflammasome activation in THP-1 treated initially with exposure to 0.2 $\mu\text{g/ml}$ LPS for 3 hours (Signal 1), followed by exposure to 10 μM nigericin for 30 min or 2 hours (Signal 2). The consecutive load of Signal 1 and Signal 2 markedly activated NLRP3 inflammasome in THP-1 cells, as indicated by production of cleaved products of CASP1 (Figure 2, panel a) and IL-1 β (Figure 2, panel b). In contrast, the introduction of Signal 1 alone was not enough to activate NLRP3 inflammasome in THP-1 cells (Figure 2, panels a and b).

Gene expression profile during NLRP3 inflammasome activation

Next, we studied the genome-wide gene expression profile of THP-1 cells pretreated with 0.2 $\mu\text{g/ml}$ LPS for 3 hours (Signal 1), washed by PBS, and exposed to 10 μM nigericin or vehicle for 2 hours (Signal 2). Then, total RNA was immediately processed for gene expression profiling on a Human Gene 1.0 ST Array. To identify NLRP3 inflammasome activation-responsive genes, we extracted the set of 83 annotated and protein-coding genes that satisfied fold change (FC) in Signal 1 (the presence of LPS versus the absence of LPS) smaller than 2-fold and FC in Signal 2 (the presence of nigericin versus the absence of nigericin) greater than 2-fold (Table 1). This gene enrichment procedure minimized the genes that were activated simply by exposure to LPS alone but not directly related to NLRP3 inflammasome activation.

Most notably, three members of NR4A nuclear receptor family, such as NR4A1 (NUR77), NR4A2 (NURR1), and NR4A3 (NOR1), were identified as those ranked within top 10 genes. Coordinated up regulation of NR4A1, NR4A2, and NR4A3 in NLRP3 inflammasome-activated THP-1 cells was validated by qPCR (Figure 3, panels a-c). Signal 1 alone mildly elevated expression of these mRNA levels, whereas introduction of Signal 2 after Signal 1 markedly elevated the levels of NR4A1, NR4A2, and NR4A3 transcripts with a 16-fold, 25-fold, or 51-fold increase, respectively. We also identified early growth response (EGR) family members, such as EGR1, EGR2, and

EGR3, which belong to a family of zinc finger transcription factors involved in the regulation of cell growth, differentiation, and survival, NF- κB inhibitor (I κB) family members, such as NFKBIZ, NFKBID, and NFKBIA, along with a panel of pro inflammatory cytokines and chemokines, including CCL3, CCL3L3, IL8, CXCL2, CCL20, IL23A, and TNFSF9, as a subgroup of NLRP3 inflammasome activation-responsive genes.

Molecular network of NLRP3 inflammasome activation responsive genes

Next, by using three different bioinformatics tools for molecular network analysis based on knowledgebase, we studied biologically relevant molecular networks for the set of 83 NLRP3 inflammasome activation-responsive genes in THP-1 cells. The core analysis of IPA identified the networks defined as “Auditory and Vestibular System Development and Function, Embryonic Development, Organ Development” ($p = 1.00\text{E-}32$), “Cell Cycle, Cellular Development, Cell Death and Survival” ($p = 1.00\text{E-}30$) (Figure 4), and “Connective Tissue Disorders, Immunological Disease, Inflammatory Disease” ($p = 1.00\text{E-}26$) as top three most relevant functional networks. These results suggest that NLRP3 inflammasome activation-responsive genes play a pivotal role in cell development, death, and immune and inflammatory responses. KeyMolnet by the neighboring network-search algorithm operating on the core contents extracted the highly complex molecular network composed of 455 molecules and 529 molecular relations. The network showed the most statistically significant relationship with canonical pathways termed as “transcriptional regulation by AP-1” ($p = 3.82\text{E-}184$), “transcriptional regulation by NR4A” ($p = 2.28\text{E-}105$), and “transcriptional regulation by EGR” ($p = 2.78\text{E-}99$) (Figure 5). These results suggest a central role of transcription factors AP-1, NR4A, and EGR in regulation of expression of NLRP3 inflammasome activation-responsive genes, by acting as a hub of the molecular network.

Finally, STRING extracted a protein-protein interaction network, composed of 35 core molecules derived from the set of 83 NLRP3 inflammasome activation-responsive genes in THP-1 cells. In this network, both the set of NR4A family members NR4A1, NR4A2, and NR4A3 and EGR transcription factors EGR1, EGR2, and EGR3 constituted a close and intense protein interaction subnetwork (Figure 6).

Table 1: The set of 83 up-regulated genes in THP-1 monocytes following activation of NLRP3 inflammasome.

Rank	FC Related to Signal 1	FC Related to Signal 2	Entrez Gene ID	Gene Symbol	Gene Name
1	1.06819645	18.61247501	8013	NR4A3	nuclear receptor subfamily 4, group A, member 3
2	1.942378012	12.91651537	6348	CCL3	chemokine (C-C motif) ligand 3
3	1.63109973	11.69111	414062	CCL3L3	chemokine (C-C motif) ligand 3-like 3
4	1.100615838	11.24166642	9308	CD83	CD83 molecule
5	1.819566773	10.85127008	3576	IL8	interleukin 8
6	1.292541852	7.633454043	1960	EGR3	early growth response 3
7	0.948867136	6.576691539	4929	NR4A2	nuclear receptor subfamily 4, group A, member 2
8	1.116320272	5.51767318	3164	NR4A1	nuclear receptor subfamily 4, group A, member 1
9	1.842348508	5.271896351	64332	NFKBIZ	nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta
10	1.268131184	4.992502002	643616	MOP-1	MOP-1
11	1.222058201	4.99018398	1959	EGR2	early growth response 2
12	1.716614387	4.456895103	5734	PTGER4	prostaglandin E receptor 4 (subtype EP4)
13	1.067764134	4.401932449	10746	MAP3K2	mitogen-activated protein kinase kinase kinase 2
14	1.076240121	4.353030131	2920	CXCL2	chemokine (C-X-C motif) ligand 2
15	1.443866138	4.329651804	6364	CCL20	chemokine (C-C motif) ligand 20
16	1.506881527	4.037790353	5743	PTGS2	prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)
17	1.143021068	3.908082725	153020	RASGEF1B	RasGEF domain family, member 1B
18	1.00701348	3.793627448	1958	EGR1	early growth response 1
19	1.188818931	3.318906546	23645	PPP1R15A	protein phosphatase 1, regulatory (inhibitor) subunit 15A
20	0.978133301	3.154899408	65125	WNK1	WNK lysine deficient protein kinase 1
21	1.116953399	3.113268501	84807	NFKBID	nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, delta
22	1.431860551	3.025219884	51561	IL23A	interleukin 23, alpha subunit p19
23	0.654486344	2.985745104	645188	LOC645188	hypothetical LOC645188
24	1.082721348	2.867304268	1843	DUSP1	dual specificity phosphatase 1
25	1.877501415	2.813972064	8870	IER3	immediate early response 3
26	1.458901009	2.788511085	9021	SOCS3	suppressor of cytokine signaling 3
27	0.930381294	2.730662487	728715	LOC728715	ovostatin homolog 2-like
28	1.251031395	2.703465614	2353	FOS	v-fos FBJ murine osteosarcoma viral oncogene homolog
29	1.994627015	2.654181457	27289	RND1	Rho family GTPase 1
30	0.877732964	2.64583117	23499	MACF1	microtubule-actin crosslinking factor 1
31	1.18363314	2.591793912	7538	ZFP36	zinc finger protein 36, C3H type, homolog (mouse)
32	0.768263434	2.584281103	79101	TAF1D	TATA box binding protein (TBP)-associated factor, RNA polymerase I, D, 41kDa
33	1.895682029	2.568793654	90668	LRRC16B	leucine rich repeat containing 16B
34	0.916615124	2.536018037	259296	TAS2R50	taste receptor, type 2, member 50
35	0.895110685	2.535538194	728741	LOC728741	hypothetical LOC728741
36	0.870604266	2.532650507	84319	CMSS1	cms1 ribosomal small subunit homolog (yeast)
37	0.474895831	2.525788794	4072	EPCAM	epithelial cell adhesion molecule
38	1.667878267	2.514873802	1326	MAP3K8	mitogen-activated protein kinase kinase kinase 8
39	1.107775084	2.496005315	8744	TNFSF9	tumor necrosis factor (ligand) superfamily, member 9
40	1.024389944	2.491488658	4616	GADD45B	growth arrest and DNA-damage-inducible, beta
41	0.97810347	2.470592388	2354	FOSB	FBJ murine osteosarcoma viral oncogene homolog B
42	1.017380957	2.461870724	643036	SLED1	RTFV9368
43	1.017380957	2.377675786	2152	F3	coagulation factor III (thromboplastin, tissue factor)

44	1.038770533	2.373054125	1973	EIF4A1	eukaryotic translation initiation factor 4A, isoform 1
45	1.596962012	2.3683134	4792	NFKBIA	nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha
46	0.872659044	2.354224669	1736	DKC1	dyskeratosis congenita 1, dyskerin
47	1.254570022	2.347010028	50515	CHST11	carbohydrate (chondroitin 4) sulfotransferase 11
48	0.818985035	2.34454831	50840	TAS2R14	taste receptor, type 2, member 14
49	0.649089802	2.278082518	85028	SNHG12	small nucleolar RNA host gene 12 (non-protein coding)
50	0.978928228	2.273044623	2889	RAPGEF1	Rap guanine nucleotide exchange factor (GEF) 1
51	0.689249392	2.247537218	55795	PCID2	PCI domain containing 2
52	0.827575589	2.246739728	54765	TRIM44	tripartite motif-containing 44
53	1.067300921	2.243145194	1263	PLK3	polo-like kinase 3 (Drosophila)
54	0.767788042	2.229552244	337867	UBAC2	UBA domain containing 2
55	1.306111439	2.229215371	3759	KCNJ2	potassium inwardly-rectifying channel, subfamily J, member 2
56	1.925222241	2.191743556	80149	ZC3H12A	zinc finger CCCH-type containing 12A
57	0.882964289	2.185060168	58155	PTBP2	polypyrimidine tract binding protein 2
58	1.545906426	2.181251323	56895	AGPAT4	1-acylglycerol-3-phosphate O-acyltransferase 4 (lysophosphatidic acid acyltransferase, delta)
59	1.05509141	2.155321381	10896	OCLM	oculomedin
60	1.05361515	2.15489714	9659	PDE4DIP	phosphodiesterase 4D interacting protein
61	0.986553364	2.153150265	3047	HBG1	hemoglobin, gamma A
62	0.87493697	2.150450624	100507607	NPIB9	nuclear pore complex interacting protein family, member B9
63	1.201327908	2.147514699	259292	TAS2R46	taste receptor, type 2, member 46
64	0.885483295	2.144478729	51574	LARP7	La ribonucleoprotein domain family, member 7
65	0.970156229	2.132807866	9839	ZEB2	zinc finger E-box binding homeobox 2
66	0.700126731	2.102345827	100133941	CD24	CD24 molecule
67	1.471640204	2.097753274	6303	SAT1	spermidine/spermine N1-acetyltransferase 1
68	0.796744464	2.080051151	9572	NR1D1	nuclear receptor subfamily 1, group D, member 1
69	1.754590053	2.069409283	10129	FRY	furry homolog (Drosophila)
70	1.117049405	2.06451372	5586	PKN2	protein kinase N2
71	1.084905208	2.058951728	339883	C3orf35	chromosome 3 open reading frame 35
72	1.007649566	2.047104863	1195	CLK1	CDC-like kinase 1
73	1.001286612	2.046307571	1185	CLCN6	chloride channel 6
74	1.005938423	2.043756057	338442	HCAR2	hydroxycarboxylic acid receptor 2
75	0.88066058	2.04297423	6144	RPL21	ribosomal protein L21
76	1.048011825	2.039547357	1844	DUSP2	dual specificity phosphatase 2
77	1.361895488	2.039480914	3092	HIP1	huntingtin interacting protein 1
78	0.951119813	2.038925421	388022	LOC388022	hypothetical gene supported by AK131040
79	0.888482949	2.018363478	144132	DNHD1	dynein heavy chain domain 1
80	0.972189862	2.012125102	23049	SMG1	SMG1 homolog, phosphatidylinositol 3-kinase-related kinase (C. elegans)
81	0.89112764	2.007348359	6181	RPLP2	ribosomal protein, large, P2
82	0.798221473	2.005195646	23329	TBC1D30	TBC1 domain family, member 30
83	1.206469961	2.003702064	3726	JUNB	jun B proto-oncogene

To activate NLRP3 inflammasome, THP-1 cells were initially exposed to 0.2 µg/ml LPS for 3 hours (Signal 1). They were then washed by PBS and exposed to 10 µM nigericin for 2 hours (Signal 2 after Signal 1). At 5 hours after initiation of the treatment, total RNA was isolated and processed for gene expression profiling on a Human Gene 1.0 ST Array. The set of 83 genes that satisfy fold change (FC) related to Signal 1 (LPS + versus LPS -) smaller than 2-fold and FC related to Signal 2 (nigericin + versus nigericin -) greater than 2-fold are shown with FC, Entrez Gene ID, Gene Symbol, and Gene Name.




Figure 4: IPA molecular network of NLRP3 inflammasome activation-responsive genes. Entrez Gene IDs corresponding to the set of 83 NLRP3 inflammasome activation-responsive genes in THP-1 cells (Table 1) were imported into the core analysis tool of IPA. The functional network defined as “Cell Cycle, Cellular Development, Cell Death and Survival” is shown. Red nodes indicate NLRP3 inflammasome activation-responsive genes.




Figure 5: KeyMolnet molecular network of NLRP3 inflammasome activation-responsive genes. Entrez Gene IDs corresponding to the set of 83 NLRP3 inflammasome activation-responsive genes in THP-1 cells (Table 1) were imported into KeyMolnet. The neighboring network-search algorithm operating on the core contents extracted the highly complex molecular network. Red nodes represent NLRP3 inflammasome activation-responsive genes, while white nodes exhibit additional nodes extracted automatically from the core contents of KeyMolnet to establish molecular connections. The molecular relation is indicated by solid line with arrow (direct binding or activation), solid line with arrow and stop (direct inactivation), solid line without arrow (complex formation), dash line with arrow (transcriptional activation), and dash line with arrow and stop (transcriptional repression). The cluster of NR4A1, NR4A2, and NR4A3 is highlighted by blue circle.

EGR family constitutes a family of zinc finger transcription factors very rapidly and transiently induced in various cell types without *de novo* protein synthesis following exposure to mitogenic signals [25,26]. EGR1 functions as a positive regulator for T and B cell functions, by regulating transcription of the genes encoding key cytokines and costimulatory molecules, while EGR2 and EGR3 act as a negative regulator essential for induction of anergy [27]. EGR1 downregulates the expression of itself by binding to an EGR1-binding site located on its own promoter [28]. Furthermore, EGR1 directly activates transcription of NR4A1 (nur77) in mouse IgM⁺ B cells [29]. Deletion of EGR2 and EGR3 in mouse T and B cells causes a lethal autoimmune syndrome characterized by excessive production of proinflammatory cytokines accompanied by overactivation of STAT1 and STAT3 [30]. Importantly, we identified SOCS3, a potent inhibitor of STAT3 activation [31], as one of NLRP3 inflammasome activation-responsive genes (Rank 26 in Table 1). These observations suggest the working hypothesis that the EGR family members are actively involved in resolution of sustained inflammation amplified by NLRP3 inflammasome activation.

Conclusion

By genome-wide gene expression profiling, we identified the set of 83 NLRP3 inflammasome activation-responsive genes in THP-1 cells. Among them, we found NR4A nuclear receptor family, EGR family, and IκB family as a group of the genes that possibly constitute a negative feedback loop for shutting down sustained inflammation following NLRP3 inflammasome activation. By molecular network analysis, we found that NLRP3 inflammasome activation-responsive genes play a pivotal role in cellular development and death, and immune and inflammatory responses, where transcription factors AP-1, NR4A, and EGR act as a hub in the molecular network.

Acknowledgement

This work was supported by the JSPS KAKENHI (C25430054), and the Intractable Disease Research Center (IDRC) project, the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan, and the grant from the National Center for Geriatrics and Gerontology (NCGC 26-20). The authors would thank Ms. Aki Takaoka for her invaluable help in microarray analysis. The microarray data are available from the Gene Expression Omnibus (GEO) under the accession number GSE58959.

References

- Schroder K, Tschopp J. The inflammasomes. *Cell*. 2010; 140: 821-832.
- Menu P, Vince JE. The NLRP3 inflammasome in health and disease: the good, the bad and the ugly. *Clin Exp Immunol*. 2011; 166: 1-15.
- Wang H, Mao L, Meng G. The NLRP3 inflammasome activation in human or mouse cells, sensitivity causes puzzle. *Protein Cell*. 2013; 4: 565-568.
- Walsh JG, Muruve DA, Power C. Inflammasomes in the CNS. *Nat Rev Neurosci*. 2014; 15: 84-97.
- Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. *Nature*. 2011; 469: 221-225.
- Shimada K, Crother TR, Karlin J, Dagvadorj J, Chiba N, Chen S, et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. *Immunity*. 2012; 36: 401-414.
- Di Virgilio F. Liaisons dangereuses: P2X(7) and the inflammasome. *Trends Pharmacol Sci*. 2007; 28: 465-472.
- Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. *Nat Immunol*. 2008; 9: 857-865.
- Jourdan T, Godlewski G, Cinar R, Bertola A, Szanda G, Liu J, et al. Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. *Nat Med*. 2013; 19: 1132-1140.
- Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, Griep A. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. *Nature*. 2013; 493: 674-678.
- Kawana N, Yamamoto Y, Ishida T, Saito Y, Konno H, Arima K, et al. Reactive astrocytes and perivascular macrophages express NLRP3 inflammasome in active demyelinating lesions of multiple sclerosis and necrotic lesions of neuromyelitis optica and cerebral infarction. *Clin Exp Neuroimmunol*. 2013; 4: 296-304.
- Gris D, Ye Z, Iocca HA, Wen H, Craven RR, Gris P, Huang M. NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses. *J Immunol*. 2010; 185: 974-981.
- Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, Lin J. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. *Nucleic Acids Res*. 2013; 41: D808-815.
- Satoh J. Bioinformatics approach to identifying molecular biomarkers and networks in multiple sclerosis. *Clin Exp Neuroimmunol*. 2010; 1: 127-140.
- Zhao Y, Brummer D. NR4A orphan nuclear receptors: transcriptional regulators of gene expression in metabolism and vascular biology. *Arterioscler Thromb Vasc Biol*. 2010; 30: 1535-1541.
- Mohan HM, Aherne CM, Rogers AC, Baird AW, Winter DC, Murphy EP. Molecular pathways: the role of NR4A orphan nuclear receptors in cancer. *Clin Cancer Res*. 2012; 18: 3223-3228.
- Sekiya T, Kashiwagi I, Yoshida R, Fukaya T, Morita R, Kimura A, Ichinose H. Nr4a receptors are essential for thymic regulatory T cell development and immune homeostasis. *Nat Immunol*. 2013; 14: 230-237.
- Bonta PI, van Tiel CM, Vos M, Pols TW, van Thienen JV, Ferreira V, et al. Nuclear receptors Nur77, Nurr, and NOR-1 expressed in atherosclerotic lesion macrophages reduce lipid loading and inflammatory responses. *Arterioscler Thromb Vasc Biol*. 2006; 26: 2288-2294.
- Saijo K, Winner B, Carson CT, Collier JG, Boyer L, Rosenfeld MG, et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. *Cell*. 2009; 137: 47-59.
- Yamaguchi H, Maruyama T, Urade Y, Nagata S. Immunosuppression via adenosine receptor activation by adenosine monophosphate released from apoptotic cells. *Elife*. 2014; 3: e02172.
- Satoh J, Tabunoki H. Molecular network of chromatin immunoprecipitation followed by deep sequencing-based vitamin D receptor target genes. *Mult Scler*. 2013; 19: 1035-1045.
- Muta T, Yamazaki S, Eto A, Motoyama M, Takeshige K. IkappaB-zeta, a new anti-inflammatory nuclear protein induced by lipopolysaccharide, is a negative regulator for nuclear factor-kappaB. *J Endotoxin Res*. 2003; 9: 187-191.
- Tergaonkar V, Correa RG, Ikawa M, Verma IM. Distinct roles of IkappaB proteins in regulating constitutive NF-kappaB activity. *Nat Cell Biol*. 2005; 7: 921-923.
- Kuwata H, Matsumoto M, Atarashi K, Morishita H, Hirotani T, Koga R, et al. IkappaBNS inhibits induction of a subset of Toll-like receptor-dependent genes and limits inflammation. *Immunity*. 2006; 24: 41-51.
- Christy B, Nathans D. DNA binding site of the growth factor-inducible protein Zif268. *Proc Natl Acad Sci U S A*. 1989; 86: 8737-8741.
- Beckmann AM, Wilce PA. Egr transcription factors in the nervous system. *Neurochem Int*. 1997; 31: 477-510.
- Gómez-Martín D, Díaz-Zamudio M, Galindo-Campos M, Alcocer-Varela J. Early growth response transcription factors and the modulation of immune

- response: implications towards autoimmunity. *Autoimmun Rev.* 2010; 9: 454-458.
28. Cao X, Mahendran R, Guy GR, Tan YH. Detection and characterization of cellular EGR-1 binding to its recognition site. *J Biol Chem.* 1993; 268: 16949-16957.
29. Dinkel A, Warnatz K, Ledermann B, Rolink A, Zipfel PF, Bürki K, et al. The transcription factor early growth response 1 (Egr-1) advances differentiation of pre-B and immature B cells. *J Exp Med.* 1998; 188: 2215-2224.
30. Li S, Miao T, Sebastian M, Bhullar P, Ghaffari E, Liu M, et al. The transcription factors Egr2 and Egr3 are essential for the control of inflammation and antigen-induced proliferation of B and T cells. *Immunity.* 2012; 37: 685-696.
31. Carow B, Rottenberg ME. SOCS3, a Major Regulator of Infection and Inflammation. *Front Immunol.* 2014; 5: 58.